The potential of exRNA has led companies like Exosome Diagnostics to develop ExoDx Lung (ALK), an exRNA-based clinical diagnostic test that measures the EML4-ALK transcript from exosomes in the plasma of NSCLC patients [498]. Here, ALK is linked to non-small cell lung carcinoma.